MedTrace Logo

Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

NCT00262483 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2007-12-21

No results posted yet for this study

Summary

To assess the safety of the combination of VX-950, Pegasys and Copegus in subjects with hepatitis C.

Conditions

  • Hepatitis C

Interventions

DRUG

VX-950

DRUG

ribavirin

DRUG

peginterferon alfa-2a

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Vertex Pharmaceuticals Incorporated

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Completion
2006-04-30

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00262483 on ClinicalTrials.gov